Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABCL575 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABCL575 | EXPERIMENTAL | Healthy participants will receive a single dose of ABCL575 administered by subcutaneous (SC) injection |
| Placebo | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo administered by subcutaneous (SC) injection |
| Name | Type | Description |
|---|---|---|
| ABCL575 | BIOLOGICAL | Participants will receive SC injection of ABCL575 |
| Placebo (Normal Saline 0.9%) | BIOLOGICAL | Participants will receive SC injection of placebo (Normal Saline 0.9%) |
Inclusion Criteria: * Healthy male or female ≥ 18 and ≤ 65 years of age at the time of screening * Good general health as determined through medical history and general physical examination * Body weight ≥ 50 and ≤ 100 Kg * Body mass index (BMI) between 18.5 kg/m2 and 30.0 kg/m2 * Non- or ex-smoker...
ABCL575 is an investigational monoclonal antibody being developed by AbCellera Biologics Inc. It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied in a first-in-human trial to evaluate its safety and tolerability.
ABCL575 is being developed by AbCellera Biologics Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol ABCL. The company is conducting a Phase 1 clinical trial of this investigational monoclonal antibody in healthy volunteers.
ABCL575 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The current Phase 1 trial is a first-in-human study designed to assess the drug's safety and tolerability.
ABCL575 is being studied in a Phase 1 clinical trial with the identifier NCT07108894. This is a first-in-human, single-ascending dose study conducted in healthy participants in Canada. The trial is randomized, double-blind, and placebo-controlled, with an enrollment of 40 participants aged 18 years and older.
Yes, ABCL575 is being tested in healthy volunteers. The ongoing Phase 1 clinical trial, NCT07108894, is specifically designed to enroll healthy participants. The study is a single-ascending dose trial, meaning different groups of participants receive increasing doses of the drug to evaluate its safety and how it is processed by the body.